MIAMI LAKES, Fla., Oct. 26, 2025 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technology, today announced the groundbreaking results from the SELUTION DeNovo and ...
The SELUTION4ISR and SELUTION DeNovo results will be presented in the first Late-Breaking Clinical Trials session on Sunday, October 26, 2025, at 11:00 a.m. PST in San Francisco. Professor Christian M ...
Cordis, a global leader in interventional cardiovascular technology, announced the groundbreaking results from the SELUTION DeNovo and SELUTION4ISR trials at Transcatheter Cardiovascular Therapeutics ...
Please provide your email address to receive an email when new articles are posted on . A sirolimus-eluting balloon was noninferior to drug-eluting stents in treating de novo coronary lesions. The ...
SAN FRANCISCO — A sirolimus-eluting balloon was found to be noninferior to conventional stenting in separate trials of patients undergoing percutaneous coronary interventions (PCIs), suggesting these ...
SAN FRANCISCO, CA—A treatment strategy that involves a novel sirolimus-eluting balloon (Selution; Cordis) performs as well as standard care when used to treat both de novo coronary artery disease and ...
SELUTION DeNovo Trial - the largest randomized Drug Eluting Balloon trial - demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions.
(MENAFN- PR Newswire) Both randomized clinical trials demonstrated positive outcomes that met primary endpoints for the SELUTION SLRTM Drug-Eluting Balloon (DEB) compared to the current standard of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results